－ Takeda plans to pursue clinical development in Japan in folate receptor-alpha(FRa) -positive ovarian cancer
－ Mirvetuximab soravtansine-gynx is the first antibody-drug conjugate developed for the treatment of ovarian cancer
OSAKA, Japan, August 29, 2023 – Takeda (TSE:4502/NYSE:TAK) announced today that it has entered into an exclusive licensing agreement with ImmunoGen, Inc. (Hereinafter referred to as ImmunoGen) to develop and commercialize mirvetuximab soravtansine-gynx (Hereinafter referred to as MIRV) for the Japanese market. MIRV is an intravenous injection antibody-drug conjugate (ADC), in which a microtubule inhibitor is linked to an anti-folate receptor-α (FRα) antibody. It is the first ADC developed for the treatment of ovarian cancer. Takeda will continue development in Japan to enable regulatory submission as a new treatment option for the treatment of FRα-positive ovarian cancer.
MIRV is approved under accelerated approval in the U.S. for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. MIRV was the first medicine to show a significant prolongation of overall survival (OS) compared with conventional chemotherapy for the treatment of platinum-resistant relapsed or refractory ovarian cancer in a phase III clinical study (MIRASOL study), conducted outside of Japan.
"We are excited to enter this agreement with ImmunoGen that enables us to expand our oncology portfolio, bringing us one step closer to achieving our aspiration to cure cancer. Ovarian cancer is diagnosed in advanced stages in many patients, is considered to be the most lethal tumor among female reproductive organ tumors, and is the ninth most common cause of cancer death in Japanese women*. We sincerely hope that MIRV, an innovative treatment developed by ImmunoGen, will be a new treatment option in this area with high unmet needs," said Satoshi Uchida, Head, Japan Oncology, Global Oncology Business Unit, Takeda.
Takeda has demonstrated a strong commitment to oncology and is committed to developing new medicines for cancer patients with limited treatment options. This license agreement serves the shared goal of our company and ImmunoGen to improve the lives of patients living with cancer worldwide.
Subject to the terms of the agreement, Takeda will obtain an exclusive license in Japan to develop and commercialize MIRV in all indications. Under the terms of the agreement, Takeda will make a one-time upfront payment and an additional payment upon conversion of US Food and Drug Administration (FDA) accelerated approval of MIRV in platinum-resistant ovarian cancer to full approval totaling 5 billion yen to ImmunoGen. In addition, milestone payments based on achievement of regulatory and sales and royalties on sales may be payable.
* Cancer Information Service: https://ganjoho.jp/public/qa_links/report/statistics/2023_jp.html
Ovarian cancer is a cancerous tumor that begins on the surface of the ovaries and in the ovaries. In Japan, approximately 13,000 cases are reported annually, of which approximately 40~50% are patients with advanced stage III or IV cancer. This type of cancer is difficult to diagnose at an early stage; in fact, 75% of patients with ovarian cancer are diagnosed with advanced cancer at the time of detection.
Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells. In November 2022, the US Food and Drug Administration (FDA) granted accelerated approval to MIRV for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens based on ORR and duration of response data from the pivotal SORAYA trial. The results from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of MIRV compared to chemotherapy in patients with FRα-positive platinum-resistant ovarian cancer (PROC) were presented at the American Society of Clinical Oncology Annual Meeting in June 2023 showing MIRV as the first novel therapy to extend overall survival in platinum-resistant disease.
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.